KOREAN DRUG CO., LTD.
Financials
Valuation Metrics
KOREAN DRUG CO., LTD.'s Market Cap is ₩311B. At end of 2025 it was ₩473B. Ranked #2013 of 2,405 in KR market (top 84%), #1273 of 1,627 on KOSDAQ (top 78%), #212 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 92%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 31.13B KRW | KR#2,013/2,405 Sec#212/231 |
| Revenue | 65.39B KRW | KR#1,645/2,405 Sec#107/231 |
| Net Income | 1.48B KRW | KR#1,448/2,405 Sec#99/231 |
| Total Assets | 94.32B KRW | KR#1,828/2,405 Sec#145/231 |
| Net Assets | 83.07B KRW | KR#1,558/2,405 Sec#125/231 |
| Employees | 172 | KR#1,203/2,405 Sec#100/231 |
| Value | ||
| P/E | 21.01x | KR#1,221/2,405 Sec#74/231 |
| P/B | 0.37x | KR#590/2,405 Sec#20/231 |
| P/S | 0.48x | KR#937/2,405 Sec#43/231 |
| EV/EBITDA | 3.41x | KR#139/2,405 Sec#2/231 |
| FCF Yield | 40.65% | KR#138/2,405 Sec#2/231 |
| Profitability | ||
| ROE | 1.78% | KR#1,421/2,405 Sec#98/231 |
| ROA | 1.57% | KR#1,295/2,405 Sec#92/231 |
| Op. Margin | 11.78% | KR#430/2,405 Sec#38/231 |
| Revenue Growth | 4.22% | KR#1,238/2,405 Sec#125/231 |
| Earnings Growth | -58.26% | KR#1,076/2,405 Sec#73/231 |
| Financial Health | ||
| Debt Ratio | 13.54% | KR#216/2,405 Sec#36/231 |
| Total Debt | 0 KRW | KR—/2,405 Sec—/231 |
| FCF | 12.65B KRW | KR#647/2,405 Sec#37/231 |
| Cash | 4.89B KRW | KR#2,003/2,405 Sec#186/231 |
| Net Debt/EBITDA | -0.63x | KR#457/2,405 Sec#25/231 |
| Dividend | ||
| Div. Yield | 6.41% | KR#184/2,405 Sec#3/231 |
| Div. Growth | 12.50% | KR#543/2,405 Sec#30/231 |
| Performance | ||
| 1Y Return | -32.62% | KR#1,547/2,405 Sec#124/231 |
| 1M Return | -13.59% | KR#1,459/2,405 Sec#149/231 |
| From 52W High | -37.80% | KR#682/2,405 Sec#43/231 |
| 1Y MDD | -37.21% | KR#466/2,405 Sec#30/231 |
| Trading | ||
| Volume | 5,412 shares | KR#2,072/2,405 Sec#209/231 |
| Trading Value | 15.1M KRW | KR#2,158/2,405 Sec#220/231 |
| Foreign Own. | 2.84% | KR#1,334/2,405 Sec#121/231 |
| Per Share | ||
| EPS | 135 KRW | KR#1,382/2,405 Sec#92/231 |
| BPS | 7,552 KRW | KR#1,180/2,405 Sec#87/231 |
Company Info
Koryo Pharm, established in 1980, manufactures and sells pharmaceuticals, listing on the KOSDAQ market in 2000. The company produces and distributes over-the-counter drugs, including Haben, a leading cold medicine in Korea, along with professional pharmaceuticals for central nervous system diseases such as dementia and epilepsy. Committed to public health, it conducts research and development for new drugs and generics, with its R&D capabilities recognized through patent applications and technology certifications. Koryo Pharm is headquartered in Icheon, Gyeonggi-do.